Ascentage Pharma Group International

Animal Exploitation (Testing): Yes Link: https://www.prnewswire.com/news-releases/ascentage-pharma-announces-ind-approval-in-china-for-phase-i-study-of-apg-5918-in-patients-with-advanced-solid-tumors-or-hematologic-malignancies-301673878.html Short Description: The company is in the business of discovering and developing new pharmaceutical drugs (oncology therapies). This process legally requires, and the company has publicly confirmed its reliance on, preclinical in vivo studies (animal models) to test the safety and anti-tumor efficacy of its drug candidates before advancing to human clinical trials. Exact Quote from Link: “In both in vitro studies and in vivo studies in animal models, the EED inhibitor APG-5918 has shown clear targeted binding and target-based antitumor activity, thus warranting further clinical evaluations.”